NEW YORK, May 2, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on HTGM, PRAH, DGX, and TROV which can be accessed for free by signing up to www.wallstequities.com/registration. Research coverage has been initiated by WallStEquities.com on HTG Molecular Diagnostics Inc. (NASDAQ:
HTG Molecular Diagnostics
Tucson, Arizona-based HTG Molecular Diagnostics Inc.'s shares declined 2.26%, closing Tuesday's trading session at $3.90. The stock recorded a trading volume of 1.16 million shares. The Company's shares have advanced 11.75% in the last month and 2.90% over the previous three months. The stock is trading 35.59% above its 200-day moving average. Additionally, shares of the Company, which develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling, have a Relative Strength Index (RSI) of 54.56.
On April 16th, 2018, HTG Molecular Diagnostics announced the promotion of John Lubniewski to President and COO. Mr. Lubniewski has served as the Company's Chief Business Officer for the past seven years, bringing over three decades of experience in the Life Science industry. Get the full research report on HTGM for free by clicking below at:
PRA Health Sciences
On Tuesday, shares in Raleigh, North Carolina headquartered PRA Health Sciences Inc. recorded a trading volume of 548,497 shares, which was above their three months average volume of 424,570 shares. The stock declined slightly by 0.54%, ending the day at $81.73. The Company's shares have advanced 0.60% in the past month and 27.80% over the past year. The stock is trading below its 200-day moving average by 1.54%. Furthermore, shares of the Company, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have an RSI of 41.99.
On April 25th, 2018, PRA Health Sciences announced the retirement of Linda Baddour, Executive Vice President and CFO, from her position as CFO, effective May 01st, 2018. Ms. Baddour will remain as Executive Vice President through September 30th, 2018 to assist with the transition of her responsibilities and act as a special advisor to the Chairman and CEO. In addition, Michael J. Bonello has been appointed by the Board of Directors as Executive Vice President and CFO, effective May 01st, 2018. PRAH's complimentary research coverage is a few simple steps away at:
Secaucus, New Jersey headquartered Quest Diagnostics Inc.'s stock finished the day 1.25% higher at $102.47 with a total trading volume of 917,009 shares. The Company's shares have advanced 4.76% in the last month. The stock is trading above its 50-day and 200-day moving averages by 0.77% and 1.81%, respectively. Additionally, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 57.00.
On April 19th, 2018, Quest Diagnostics announced its results for Q1 ended March 31st, 2018. For the quarter, net revenues were $1,884 million, operating income was $272 million, and net income attributable to the Company was $177 million. Diluted EPS was $1.27 for Q1 2018, cash provided by operations was $180 million, and capital expenditures were $73 million.
On May 01st, 2018, research firm Robert W. Baird upgraded the Company's stock rating from 'Neutral' to 'Outperform'. Register for your free research report on DGX at:
Shares in San Diego, California headquartered TrovaGene Inc. ended yesterday's session 0.53% lower at $0.28. The stock recorded a trading volume of 595,525 shares. The Company's shares are trading 19.27% below their 50-day moving average. Moreover, shares of TrovaGene have an RSI of 38.02.
On April 17th, 2018, TrovaGene announced the presentation of pharmacodynamic and biomarker data from the first patient to complete a safety treatment cycle in its Phase-1b/2 clinical trial of PCM-075, a highly-selective Polo-like Kinase 1 Inhibitor, in Acute Myeloid Leukemia. PCM-075 appeared to be well tolerated with the first of three patients enrolled in the initial Phase-1b dose-escalation cohort consenting to, and completing, a second cycle of treatment with PCM-075 plus LDAC. Wall St. Equities' downloadable research report on TROV available at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-medical-research-stocks----htg-molecular-diagnostics-pra-health-sciences-quest-diagnostics-and-trovagene-300640944.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ...
Patisiran injection, recently approved by FDA to treat polyneuropathy, a disease that causes ...
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...View All